



Clinical Trial Supply New England 2024

Boston, Massachusetts
9th -10th April 2024
www.arena-international.com/ctsnewengland/



Arena will be returning to the Westin Waltham for our 2024 Clinical Trial Supply, New England conference. The event will showcase talks from top industry players, unrivaled networking opportunities and the chance to find cutting-edge solutions in the exhibition hall.

Speakers 2024:

- Anthony Thomas, Consumer Safety Officer, FDA
- Stephen King, Compliance Officer, FDA
- Sean Smith, Biological Threat Exclusion Coordinator (BTEC), US Customs and Border Protection
- Paul Larochelle, Director, Global Clinical Supply Chain, Takeda
- Sydney Reynolds, Postdoctoral Fellow Global Clinical Supply Chain, Takeda
- Amanda Murphy, Senior Director, Data Intelligence & Solutions, Global Data
- Scott Sutton, Senior Director, Clinical Supply Chain, Constellation Pharmaceuticals, a MorphoSys company
- Rajiv Panwar, VP, CMC, Technical Operations and Clinical Supply Chain, Disc Medicine
- Jessica Vieira, Global Value Chain Environmental Sustainability Strategy Lead, Takeda
- Sarah Mandlebaum, Lead, Global Environmental Sustainability & Life Cycle Assessment, Takeda
- Rakibou Ouro-Djobo, Global Clinical Supply Chain & Logistics Lead, Bill & Melinda Gates
 Medical Research Institute
- Gilad Beck, Site Head, Operations and Manufacturing Director, Orgenesis
- Agnes Jung, VP, Head of Clinical Development and Operations, Bridge Biotherapeutics
- Jamie Myers, Senior Manager Clinical Supply Chain, Takeda
- Lisa Kaufman, Associate Director, Quality, Process and Risk Management, AstraZeneca

APRIL 9TH & 10TH | BOSTON, MA

DAY 1 - TUESDAY APRIL 9TH

8:15	Registration and refreshments
8:50	Chairperson's opening remarks Amanda Murphy, Senior Director, Data Intelligence & Solutions, Global Data
9:00	Importing FDA regulated Biological Products • Entry Screening/Admissibility • FDA Regulatory Requirements for CBER Regulated Products • Making ACE Work for You: Importing Biological Products
	Anthony Thomas, Consumer Safety Officer, FDA Stephen King, Compliance Officer, FDA
9:30	Reserved for N-Side
10:00	Optimizing forecasting: size-phase appropriate approaches Implementing forecasting techniques tailored to the specific size and phase of the project. Discussing strategies for dynamically adjusting forecasting methods as the project progresses through different phases Exploring how size-phase appropriate forecasting can enhance risk management and improve decision making in diverse project scenarios
	Scott Sutton, Senior Director, Supply Chain, Constellation Pharmaceuticals, a MorphoSys company
10:30	Morning refreshments and networking
11:00	Modernizing the way drugs are made: a transition to continuous manufacturing Exploring batch vs continuous manufacturing Pinpointing benefits of continuous manufacturing- reduced manufacturing costs, particularly over the long term, shorter production times, improved quality A challenging but worthwhile transition revamping industry infrastructure
	Rajiv Panwar, VP, CMC, Technical Operations and Clinical Supply Chain, Disc Medicine
11:45	Reserved for Mercalis



APRIL 9TH & 10TH | BOSTON, MA

12:15	 State of the biopharma industry: the outlook for drugs, trials, and manufacturing What's coming in the pharma pipeline? Drug manufacturing for clinical trials Emerging trends: gene therapy, mRNA, and Al Opportunities for contract development and manufacturing organisations (CDMOs) Amanda Murphy, Senior Director, Data Intelligence & Solutions, Global Data
12:45	Lunch and networking
1:45	 Optimizing drug utilization: strategies to tackle drug waste in healthcare Exploring how precision medicine and personalized dosing can be leveraged to minimize drug overuse and reduce waste, considering factors such as patient variability and therapeutic response. Discussing improvements in supply chain management to prevent overstocking and expiration of medications, emphasizing collaboration between healthcare providers and pharmaceutical suppliers to streamline inventory and reduce waste. Highlighting the importance of patient education and adherence initiatives in reducing unnecessary drug consumption, and explore how healthcare professionals can work with patients to enhance understanding and compliance, ultimately minimizing medication waste Lisa Kaufman, Associate Director, Quality, Process and Risk Management, AstraZeneca
2:15	Reserved for Boostcode
2:45	 A greener future for patients: the pharma supply chain's journey to net-zero Starting sustainability Discovering continuous manufacturing as a way to generate 80% less carbon emissions Exploring new technology to entirely replace natural resources with a fermentation-based method Reducing carbon emissions caused by cold chain shipping by investing in greener fuels and energy sources for transport vehicles Jessica Vieira, Global Value Chain Environmental Sustainability Strategy Lead, Takeda Sarah Mandlebaum, Lead, Global Environmental Sustainability & Life Cycle Assessment, Takeda
3:15	Afternoon refreshments and networking
3:45	 Investigating the necessities surrounding the import and export of biological materials Emphasizing the critical role of thorough preparation What relevant authorities to contact in advance to avoid unnecessary complications CBP One – an application that allows scheduling inspection appointments in advance for biological products upon their air arrival into the U.S.



APRIL 9TH & 10TH | BOSTON, MA

	 Understanding what Importer of Record is and how to become a registered one Sean Smith, Biological Threat Exclusion Coordinator, US Customs and Border Protection
4:15	Reserved for event sponsor
4:45	 PANEL DISCUSSION Discovering the evolution in the clinical supply chain Exploring the role of emerging technologies, such as blockchain, IoT, and AI, in revolutionizing the clinical supply chain and discuss how these innovations enhance visibility, traceability, and efficiency. Discussing the evolving regulatory landscape and its impact on the clinical supply chain, focusing on how industry players are navigating compliance challenges and ensuring alignment with changing regulations. Examining the shift toward patient-centricity in clinical trials and its influence on the supply chain, emphasizing how personalized medicine, decentralized trials, and direct-to-patient models are shaping the evolution of clinical supply strategies. Moderator Amanda Murphy, Senior Director, Data Intelligence & Solutions, Global Data Panelists Gilad Beck, Site Head, Operations and Manufacturing Director, Orgenesis Agnes Jung, VP, Head of Clinical Development and Operations, Bridge Biotherapeutics
5:30	Chairperson's closing remarks



DAY 2 – WEDNESDAY APRIL 10TH

8:15am | Registration and refreshments



APRIL 9TH & 10TH | BOSTON, MA

8:50am	Chairperson's opening remarks
	PROBLEM-SOLVING ROUNDTABLE DISCUSSIONS During the roundtable discussion session, the conference hall will be divided into three 'zones'. Delegates can choose which zone they would like to join. Each zone will be led by a table moderator and will focus on a different challenge within clinical supply chains. After 45 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.
9:00 ROUNDTABLE	ROUNDTABLE 1: A Q&A session examining U.S. Customs and Border Protection – help with any questions about how to import or export biological materials to or from the U.S.
	Sean Smith, Biological Threat Exclusion Coordinator, US Customs and Border Protection
	ROUNDTABLE 2: Effective strategies for strengthening the relationship with CDMOs Rajiv Panwar, VP, CMC, Technical Operations and Clinical Supply Chain, Disc Medicine
	ROUNDTABLE 3: Exploring Effective Strategies for Small Sponsors to Select the Right Vendor and Ensure High Quality Output
	ROUNDTABLE 4: Understanding Impacts of New EU Clinical Trial Regulation on Supply Chain
10:30	Morning refreshments and networking
11:00	 Understanding strategies for preventing shortages and enhancing resilience in supply chain Delving into the importance of building resilient clinical supply systems, exploring technologies and methodologies that enhance agility and responsiveness to prevent shortages in the face of unforeseen challenges Discussing strategies for effective comparator sourcing, addressing potential bottlenecks, and exploring partnerships or alternative sourcing approaches to ensure a stable and consistent supply of comparators for clinical trials
	 Explore considerations and approaches for removing comparators from the free market, examining the potential impact on supply stability and discussing measures to mitigate market-related risks, ensuring a reliable and sustainable clinical supply chain
	Rakibou Ouro-Djobo, Global Clinical Supply Chain & Logistics Lead, Bill & Melinda Gates Medical Research Institute



APRIL 9TH & 10TH | BOSTON, MA

-		
11:30	Reserved for event sponsor	
	Exploring how decentralized manufacturing can enhance clinical trial supply	
	High level overview of decentralized manufacturing – understanding what it means, the approach and how it's done in practice	
12:00	 Recognizing how decentralized manufacturing can improve resilience of clinical trial supply Maximizing upstream and downstream clinical supply efficiency through a decentralized framework Envisioning the future of decentralized manufacturing and exploring its potential 	
	Gilad Beck, Site Head, Operations and Manufacturing Director, Orgenesis	
12:45	Lunch and networking	
	Fostering a Dynamic Team Culture for Talent Development	
0.00	 Cultivating collaborative team dynamics Emphasizing the value of diverse thinking for problem-solving and creative solutions 	
2:00	Implementing ongoing training programs to upskill team members and address skill gaps	
	Providing mentorship and coaching opportunities to nurture individual growth	
	Paul Larochelle, Director, Global Clinical Supply Chain, Takeda	
	Sydney Reynolds, Postdoctoral Fellow - Global Clinical Supply Chain, Takeda	
	PANEL DISCUSSION	
	Harmonizing temperature excursion management: navigating conflicting policies at investigative sites	
	Addressing the challenges of integrating site-specific temperature excursion policies with the sponsor's requirements and proposing effective extratogical for alignment.	
	requirements and proposing effective strategies for alignment. • Emphasizing the importance of open communication between sponsors and investigative sites to identify	
2:30	and resolve conflicts in temperature excursion management procedures.	
	 Exploring the implementation of standardized procedures that accommodate both site-specific policies and sponsor requirements, ensuring effective temperature excursion management while respecting local protocols 	
	Moderator Amanda Murphy, Senior Director, Data Intelligence & Solutions, Global Data	
	Panelists	



Sales Enquiry
Jarvinder Sidhu
Senior Sponsorship Sales
T: +44 (0)207 9472755
E: jazsidhu@arena-international.com

Speaker Enquiry
Ralitsa Pashkuleva
CTS Portfolio Manager
E: ralitsa.pashkuleva@arenainternational.com

Marketing Enquiry
Haida Amirzadah
Marketing Manager
E: Haida.Amirzadah@arenainternational.com

APRIL 9TH & 10TH | BOSTON, MA

$\mathcal{S}($	Rakibou Ouro-Djobo, Global Clinical Supply Chain & Logistics Lead, Bill & Melinda Gates Medical Research Institute Jamie Myers, Senior Manager Clinical Supply Chain, Takeda
0.00	
3:00	Chairperson's closing remarks

END OF CONFERENCE



Sales Enquiry
Jarvinder Sidhu
Senior Sponsorship Sales
T: +44 (0)207 9472755
E: jazsidhu@arena-international.com

Speaker Enquiry
Ralitsa Pashkuleva
CTS Portfolio Manager
E: ralitsa.pashkuleva@arenainternational.com

Marketing Enquiry
Haida Amirzadah
Marketing Manager
E: Haida.Amirzadah@arenainternational.com